ARS Pharmaceuticals Future Growth
Future criteria checks 5/6
ARS Pharmaceuticals is forecast to grow earnings and revenue by 69.8% and 55.5% per annum respectively while EPS is expected to grow by 69.2% per annum.
Key information
69.8%
Earnings growth rate
69.2%
EPS growth rate
| Biotechs earnings growth | 28.4% |
| Revenue growth rate | 55.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 14 Nov 2024 |
Recent future growth updates
Recent updates
ARS Pharmaceuticals: Demand Curve Is Key Unknown
Nov 20We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow
Sep 13
ARS Pharmaceuticals: A Decent Bet For Upside After Neffy Approval
Sep 06ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles
Jun 25We're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Rate
Mar 18ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans
Nov 14Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation
May 12Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 219 | 6 | -86 | 8 | 4 |
| 12/31/2025 | 115 | -44 | -166 | -44 | 4 |
| 12/31/2024 | 28 | -48 | 80 | -57 | 4 |
| 9/30/2024 | 3 | -49 | -46 | -46 | N/A |
| 6/30/2024 | 1 | -45 | -44 | -44 | N/A |
| 3/31/2024 | 0 | -50 | -54 | -54 | N/A |
| 12/31/2023 | 0 | -54 | -59 | -59 | N/A |
| 9/30/2023 | 0 | -62 | -63 | -62 | N/A |
| 6/30/2023 | 0 | -53 | -56 | -55 | N/A |
| 3/31/2023 | 1 | -42 | -46 | -46 | N/A |
| 12/31/2022 | 1 | -35 | -40 | -40 | N/A |
| 9/30/2022 | 2 | -25 | -25 | -25 | N/A |
| 6/30/2022 | 2 | -25 | -24 | -24 | N/A |
| 3/31/2022 | 4 | -23 | -21 | -21 | N/A |
| 12/31/2021 | 6 | -20 | -18 | -18 | N/A |
| 12/31/2020 | 18 | -1 | 9 | 9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SPRY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: SPRY is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SPRY is expected to become profitable in the next 3 years.
Revenue vs Market: SPRY's revenue (55.5% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: SPRY's revenue (55.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SPRY's Return on Equity is forecast to be high in 3 years time